For the quarter ending 2025-06-30, TNFA had $34,399 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-06-30 |
|---|---|
| Options issued to non-employees | 44,219 |
| Options issued to directors | 110,168 |
| Net loss | -2,920,938 |
| Prepaid expenses | 445,773 |
| Operating leases | 0 |
| Deferred compensation payable | 0 |
| Trade and other payables | -224,954 |
| Change in fair value of warrants | 0 |
| Options issued to key employees | 35,103 |
| Loss on issuance of series g convertible preferred stock | 0 |
| Loss on issuance of series f-1 convertible preferred stock | 0 |
| (gain) on sale of marketable securities | 2,176 |
| Change in fair value of marketable securities | -1,744 |
| Change in fair value of derivatives | 1,303,000 |
| Net cash used by operating activities | -4,705,607 |
| Proceeds from sale of marketable securities | 10,659,546 |
| Purchases of marketable securities | 5,919,540 |
| Net cash provided by/(used in) investing activities | 4,740,006 |
| Redemption of series f convertible preferred stock | 0 |
| Proceeds from issuance of series f-1 convertible preferred stock | 0 |
| Proceeds from the issuance of series g convertible preferred stock | 0 |
| Dividends on preferred stock | 0 |
| Premium on series f convertible preferred stock | 0 |
| Net cash provided by financing activities | 0 |
| Net decrease in cash | 34,399 |
TNF Pharmaceuticals, Inc. (TNFA)
TNF Pharmaceuticals, Inc. (TNFA)